IVERIC bio, Inc. (ISEE)
IVERIC bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Parsippany, NJ, US. The stock last traded at $39.95, up 0.38% on the session, giving a market capitalisation of $5.51B. On trailing twelve-month figures it carries a trailing P/E of -27.55, a net margin of 0.0%. Its beta of 1.10 implies it has historically moved more than the broad market.
IVERIC bio, Inc. is a biopharmaceutical enterprise focused on identifying and advancing innovative therapeutic solutions for eye conditions, with a particular emphasis on age-related and rare inherited retinal diseases (IRDs). A cornerstone of its development pipeline is Zimura, an inhibitor targeting complement factor C5. This compound is currently undergoing investigation for geographic atrophy (GA), a severe form of dry age-related macular degeneration (AMD). Zimura's clinical progression includes the GATHER1 trial, which has successfully concluded its Phase 2/3 stage, and the GATHER2 trial, which is presently in Phase 3. The company's portfolio also features STAR (identified as OPH2005), a candidate in Phase 2b clinical trials for addressing Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1). Additionally, IVERIC bio is developing IC-500, a high-temperature requirement A serine peptidase 1 protein inhibitor intended for GA and other forms of age-related retinal degeneration. Other programs include IC-100, aimed at rhodopsin-mediated autosomal dominant retinitis pigmentosa, and IC-200, designed for IRDs stemming from mutations in the BEST1 gene. Beyond these active programs, the company has completed several earlier clinical trials: OPH2001, a Phase 1/2a study evaluating various doses of Zimura monotherapy for GA; OPH2000, a Phase 1/2a trial assessing different doses of Zimura combined with Lucentis for wet AMD; OPH2007, which concluded its Phase 2a study for wet AMD; and OPH2002, a Phase 2a trial for idiopathic polypoidal choroidal vasculopathy. In its earlier-stage research and discovery efforts, IVERIC bio is exploring programs such as miniCEP290 for LCA10, miniABCA4 for STGD1, and miniUSH2A for Usher syndrome type 2A-related IRDs. Established in 2007, the company, originally known as Ophthotech Corporation, adopted its current name, IVERIC bio, Inc., in April 2019. Its operations are based in Parsippany, New Jersey.
IVERIC bio, Inc. is most often compared with the following Healthcare names: